Eplerenone as a Supplement to Epidural Steroid Injections

University of Cincinnati

Status and phase: Withdrawn; Phase 4

Conditions: Sciatic Radiculopathy; Low Back Pain; Degenerative Intervertebral Discs

Treatments: Drug: Placebo Oral Tablet; Drug: Eplerenone 50 Mg Tab

Study type: Interventional

Funder types: Other

Identifiers

NCT03418649

2017-2713

Details and patient eligibility

About

Low back pain is a leading cause of disability and health care costs in the United States, and treatments are ineffective for many patients. Epidural steroid injections are a common treatment, but their efficacy has been questioned and for many patients they do not provide complete relief. The investigators hypothesize, based on preclinical studies, that lack of complete efficacy may be due to the fact that clinically used steroids activate not only the intended drug target, the glucocorticoid receptor, but also the pro-inflammatory mineralocorticoid receptor. To test this hypothesis, this pilot study will recruit patients scheduled for lumbar epidural steroid injections for degenerative disc disease, and randomize them to receive a concurrent treatment with oral eplerenone (a clinically approved antagonist of the mineralocorticoid receptor) or placebo for 10 days starting just after the epidural injection. At several time points during the following year, subjects will answer the Oswestry Low Back Pain Questionnaire, to report on both pain and functional outcomes.

Full description

Patients with degenerative disc disease, who are recommended to have an epidural steroid injection at the participating clinics, as part of their routine clinical care, will be invited to participate in the study prior to their first epidural steroid injection. If they consent, they will complete the Oswestry Low Back Pain Questionnaire (version 2) just prior to their first injection which captures the functional effects of back pain on various activities, providing a more meaningful picture than a simple static pain rating.

The subjects will complete the Oswestry Low Back Pain Questionnaire again four weeks after their first injection, a time point at which patients routinely have a follow-up visit. Patients referred for a second injection at this time will complete an additional Oswestry just prior to that injection. Subjects will be asked to complete additional Oswestry Low Back Pain Questionnaires at 3 months, 6 months, 1 year after their epidural injection (or after their second epidural injection if this is recommended).

Prior to receiving study medication (eplerenone or placebo), subjects will provide a blood sample to examine their creatinine and potassium levels, to ensure there are no contraindications to taking eplerenone. C reactive protein levels will also be measured just prior to epidural steroid injections to determine whether this can help predict the response.

In addition to the pain questionnaires, data will be collected from the subjects' medical charts regarding basic clinical demographics and clinical outcome of the epidural steroid injection.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of lumbar degenerative disc disease demonstrated on either lumbar X-Ray or lumbar MRI.
• radicular symptoms or electromyograph consistent with radiculopathy and exam findings corresponding to this diagnosis
• Scheduled for lumbar epidural steroid injection at participating clinics as part of routine clinical care
• Negative pregnancy test, if of childbearing potential

Exclusion criteria

• Unable to complete questionnaires or give informed consent in English
• Unavailable for follow-up contacts to complete questionnaires
• Renal impairment (estimated glomerular filtration rate <50 mL/min or serum creatinine >1.8mg/dL) on metabolic panel obtained just prior to epidural injections.
• Elevated serum potassium (>5.5 milliequivalents/L) on metabolic panel obtained just prior to epidural injections.
• Have undergone previous lumbar surgery within the past year.
• Treated with lumbar epidural steroid injection within the past 3 months at the time of consent.
• Diabetic
• Systolic blood pressure reading less than 100 mm Hg at most recent pain clinic visit.
• Prescribed protease inhibitors.
• Taking strong CYP3A4 inhibitors
• Taking potassium supplements or potassium-sparing diuretics (amiloride, spironolactone, or triamterene) or using salt substitutes that contain potassium (examples given below and in the prescreening document to be used by the study nurse).
• Lactating.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

0 participants in 2 patient groups, including a placebo group

Experimental

Experimental group

Description:

Eplerenone 50 Mg Tab

Treatment:

Drug: Eplerenone 50 Mg Tab

Control

Placebo Comparator group

Description:

Placebo Oral Tablet

Treatment:

Drug: Placebo Oral Tablet